Amgen Inc. (AMGN): Who It Depends On
Amgen manufactures the large majority of its biologics in-house, so its real supply-chain bottleneck sits with the third-party contract manufacturers and single-source raw-material and packaging suppliers its own 10-K flags as risk factors, including a confirmed relationship with West Pharmaceutical Services for vial and stopper packaging on select products. On the revenue side, Amgen's own 10-K discloses that three large wholesalers - McKesson, Cencora, and Cardinal Health - together accounted for 77% of worldwide gross product sales in 2025, with each individually exceeding 10% of total revenue, making US drug-distributor concentration by far the more precisely disclosed of the two stories.
Supply-chain dependency
Companies AMGN relies on to design, manufacture, package, and assemble its hardware.
Not a single company. Amgen's own 10-K discloses that it uses third-party contract manufacturers "to supplement the capacity or capability of our commercial manufacturing network," without naming specific partners.
Not a single company. Amgen's 10-K warns that certain raw materials, medical devices, and components used in commercial and clinical manufacturing are supplied by unaffiliated third parties, "certain of which may be our only source."
A confirmed packaging supplier - Amgen has publicly selected West's polymer vials and Daikyo Crystal Zenith vial technology for its injectable products, a real, sourced relationship rather than an industry-pattern estimate.
Not a single company. Biologics manufacturers broadly depend on a small group of specialized suppliers for single-use bioreactor bags, filtration media, and cell-culture inputs; no Amgen-specific relationship with an individual supplier in this category was confirmed in public disclosures.
Not a single company. Amgen's biologic products require temperature-controlled storage and transport, adding a logistics dependency layered on top of its manufacturing and packaging supply chain.
Customer concentration
Companies that make up an outsized share of AMGN's revenue - who AMGN relies on to buy from it.
One of the "Big Three" US pharmaceutical wholesalers; Amgen's own 10-K discloses that McKesson individually accounted for more than 10% of total revenue in 2025, and that the three largest wholesalers combined for 77% of worldwide gross product sales.
Formerly AmerisourceBergen, and another of Amgen's three largest wholesale distributors, individually exceeding 10% of total revenue per Amgen's own 10-K disclosure.
The third of Amgen's "Big Three" wholesale distributors, also individually above 10% of total revenue - together with McKesson and Cencora, these three companies moved 77% of Amgen's worldwide gross product sales in 2025.
Not a single company. The remainder of Amgen's revenue flows through smaller wholesalers, specialty pharmacies, group purchasing organizations, and direct sales arrangements outside its three dominant distributors.
The percentages shown are editorial estimates based on public research (company disclosures, earnings commentary, and industry reporting) meant to illustrate relative reliance, not precise or audited figures. Companies without a proper, reliably tradable ticker on this site are shown without stock/earnings links. This is not financial advice.
Continue Exploring
More ways to dig into the market on MyStockHarbor.